Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy

Chinese Journal of Cancer

Volumn 32, Issue 7, 2013, Pages 376-379

  Tan, Jing ^a   Yu, Qiang ^a,b,c  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Drug resistance; MYC; PDK1; PI3K mTOR pathway; Targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; BX 912; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TORIN 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RESEARCH; CANCER RESISTANCE; DRUG RESEARCH; DRUG RESPONSE; DRUG SENSITIVITY; FEEDBACK SYSTEM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENES, MYC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84879833652     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10287     Document Type: Review

References (33)

1. Engelman J A, Luo J, Cantley L C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet, 2006,7:606-619.
2. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev, 2010,20:87-90.
3. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PICK3CA gene in human cancers. Science, 2004,304:554
4. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 1997,275:1943-1947.
5. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell, 2007,12:9-22.
6. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer, 2006,6:729-734.
7. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev, 2004,18:1926-1945.
8. Dowling RJ, Topisirovic I, Alain T, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science, 2010,328:1172-1176.
9. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal, 2009,2:pe24.
10. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell, 2006,22:159-168.
11. Carracedo A, Baselga J, Pandolfi PP. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle, 2008,7:3805-3809.
12. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest, 2008,118:3065-3074.
13. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res, 2006,66:1500-1508.
14. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/ mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell, 2006,9:341-349.
15. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther, 2008, 7:1851-1863.
16. Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med, 2010,16:205-213.
17. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005,307:1098-1101.
18. Hsieh AC, Costa M, Zollo O, et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-EIF4E. Cancer Cell, 2010,17:249-261.
19. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/ mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res, 2008,68:8022-8030.
20. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med, 2006,12:122-127.
21. Tan J, Lee PL, Li Z, et al. B55beta-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell, 2010,18:459-471.
22. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell, 2011,19:575-586.
23. Liu P, Cheng H, Santiago S, et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med, 2011,17:1116-1120.
24. Ilic N, Utermark T, Widlund HR, et al. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A, 2011,108:E699-708.
25. Muellner MK, Uras IZ, Gapp BV, et al. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol, 2011,7:787-793.
26. Dang CV. Myc on the path to cancer. Cell, 2012,149:22-35.
27. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell, 2011,146:904-917.
28. Kessler JD, Kahle KT, Sun T, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science, 2012,335:348-353.
29. Kress TR, Cannell IG, Brenkman AB, et al. The MK5/PRAK kinase and Myc form a negative feedback loop that is disrupted during colorectal tumorigenesis. Mol Cell, 2011,41:445-457.
30. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature, 2011,478:524-528.
31. Ericson K, Gan C, Cheong I, et al. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci U S A, 2010,107:2598-2603.
32. Peifer C, Alessi D R. Small -molecule inhibitors of P D K 1. Chem Med Chem, 2008, 3:1810-1838.
33. Maurer M, Su T, Saal LH, et al. 3-phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res, 2009,69:6299-6306.